These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23851429)

  • 21. Endocrine tumors of the pancreas.
    Simon P; Spilcke-Liss E; Wallaschofski H
    Endocrinol Metab Clin North Am; 2006 Jun; 35(2):431-47, xii. PubMed ID: 16632104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and characterization of islet cell tumor in pTet-on/pTRE-SV40Tag double-transgenic mice model.
    Shen Q; Sun Q; Wei X; Dong J; Zhang R; Wu P; Jin Y; Feng J; Li H; Hu Y
    J Biosci Bioeng; 2007 Jul; 104(1):14-21. PubMed ID: 17697978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors.
    Chatani PD; Agarwal SK; Sadowski SM
    Front Endocrinol (Lausanne); 2020; 11():575620. PubMed ID: 33537001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular phenotype of simian virus 40 large T antigen-induced primitive neuroectodermal tumors in four different lines of transgenic mice.
    Fung KM; Chikaraishi DM; Suri C; Theuring F; Messing A; Albert DM; Lee VM; Trojanowski JQ
    Lab Invest; 1994 Jan; 70(1):114-24. PubMed ID: 7508007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
    Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
    Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm.
    Karakaxas D; Gazouli M; Liakakos T; Vaiopoulou A; Apessou D; Papaparaskeva K; Patapis P; Dervenis C
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):826-35. PubMed ID: 24987821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular pathogenesis and targeted therapy of sporadic pancreatic neuroendocrine tumors.
    Capurso G; Archibugi L; Delle Fave G
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):594-601. PubMed ID: 25619712
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALCAM is associated with chemoresistance and tumor cell adhesion in pancreatic cancer.
    Hong X; Michalski CW; Kong B; Zhang W; Raggi MC; Sauliunaite D; De Oliveira T; Friess H; Kleeff J
    J Surg Oncol; 2010 Jun; 101(7):564-9. PubMed ID: 20461761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
    Lee LC; Grant CS; Salomao DR; Fletcher JG; Takahashi N; Fidler JL; Levy MJ; Huebner M
    Surgery; 2012 Dec; 152(6):965-74. PubMed ID: 23102679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathology diagnosis of pancreatic neuroendocrine tumors.
    Kasajima A; Yazdani S; Sasano H
    J Hepatobiliary Pancreat Sci; 2015 Aug; 22(8):586-93. PubMed ID: 25641911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The evolving landscape of neuroendocrine tumors.
    Bergsland EK
    Semin Oncol; 2013 Feb; 40(1):4-22. PubMed ID: 23391109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting pancreatic expressed PAX genes for the treatment of diabetes mellitus and pancreatic neuroendocrine tumors.
    Martin-Montalvo A; Lorenzo PI; López-Noriega L; Gauthier BR
    Expert Opin Ther Targets; 2017 Jan; 21(1):77-89. PubMed ID: 27841034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
    Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
    Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Internexin: a novel biomarker for pancreatic neuroendocrine tumor aggressiveness.
    Liu B; Tang LH; Liu Z; Mei M; Yu R; Dhall D; Qiao XW; Zhang TP; Zhao YP; Liu TH; Xiao Y; Chen J; Xiang HD; Wu HY; Lu CM; Lv B; Zhou YR; Zhang Y; Deng D; Chen YJ
    J Clin Endocrinol Metab; 2014 May; 99(5):E786-95. PubMed ID: 24483152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetics of Pancreatic Neuroendocrine Tumors.
    Mohindroo C; McAllister F; De Jesus-Acosta A
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic neuroendocrine tumors: Therapeutic challenges and research limitations.
    Mpilla GB; Philip PA; El-Rayes B; Azmi AS
    World J Gastroenterol; 2020 Jul; 26(28):4036-4054. PubMed ID: 32821069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystic pancreatic neuroendocrine tumors: A distinctive subgroup with indolent biological behavior? A systematic review and meta-analysis.
    Zhu JK; Wu D; Xu JW; Huang X; Jiang YY; Edil BH; Li M; Hu SY; Zhan HX
    Pancreatology; 2019 Jul; 19(5):738-750. PubMed ID: 31160191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemotherapy for GI and pancreatic NETs].
    Doi T
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):838-42. PubMed ID: 23863723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior.
    Liu M; Imam H; Oberg K; Zhou Y
    Neuroendocrinology; 2005; 82(1):1-10. PubMed ID: 16293970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.